V. Bezlyak

发表

Validation of Magnetic Resonance Myocardial Perfusion Imaging With Fractional Flow Reserve for the Detection of Significant Coronary Heart Disease

I. Ford, K. Oldroyd, H. Dargie, 2009, Circulation.

Psychological, social and biological determinants of ill health (pSoBid): Study Protocol of a population-based study

N. Sattar, I. Ford, C. Packard, 2008, BMC public health.

Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections.

C. Weir, R. Seaton, V. Bezlyak, 2011, International journal of antimicrobial agents.

Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis

M. Larsen, V. Bezlyak, S. Regnier, 2015, BMJ Open.

How do patients with secondary progressive multiple sclerosis enrolled in the EXPAND randomized controlled trial compare with those seen in German clinical practice in the NeuroTransData multiple sclerosis registry?

V. Bezlyak, N. Adlard, A. Bergmann, 2022, Journal of central nervous system disease.

Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.

S. Androudi, A. Dick, İ. Tuğal-Tutkun, 2013, Ophthalmology.

Reduced Glomerular Filtration Rate and Its Association with Clinical Outcome in Older Patients at Risk of Vascular Events: Secondary Analysis

N. Sattar, A. D. de Craen, J. Jukema, 2009, PLoS medicine.

Differences in atherosclerosis according to area level socioeconomic deprivation: cross sectional, population based study

N. Sattar, I. Ford, C. Packard, 2009, BMJ : British Medical Journal.

Profile of microvolt T‐wave alternans testing in 1003 patients hospitalized with heart failure

J. McMurray, M. Petrie, I. Ford, 2012, European journal of heart failure.

25-Hydroxyvitamin D is lower in deprived groups, but is not associated with carotid intima media thickness or plaques: results from pSoBid.

I. Ford, C. Packard, A. McConnachie, 2012, Atherosclerosis.

Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial

V. Bezlyak, C. McCloskey, A. Taha, 2009, The Lancet.

Efficacy of Anti-VEGF and Laser Photocoagulation in the Treatment of Visual Impairment due to Diabetic Macular Edema: A Systematic Review and Network Meta-Analysis

V. Bezlyak, S. Regnier, W. Malcolm, 2014, PloS one.

Red cell distribution width has incremental prognostic value to B‐type natriuretic peptide in acute heart failure

J. McMurray, M. Petrie, I. Ford, 2009, European journal of heart failure.

Cognitive behaviour therapy for violent men with antisocial personality disorder in the community: an exploratory randomized controlled trial

M. Crawford, I. Ford, P. Tyrer, 2008, Psychological Medicine.

SIERRA-AMD: A Retrospective, Real-World Evidence Study of Patients with Neovascular Age-Related Macular Degeneration in the United States.

V. Bezlyak, A. Sagkriotis, A. Khanani, 2019, Ophthalmology. Retina.

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

A. Wenzel, F. Fajnkuchen, V. Bezlyak, 2015, British Journal of Ophthalmology.

Early life socioeconomic adversity is associated in adult life with chronic inflammation, carotid atherosclerosis, poorer lung function and decreased cognitive performance: a cross-sectional, population-based study

Jonathan Cavanagh, Carol Tannahill, Vladimir Bezlyak, 2011, BMC public health.

Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients

G. Liew, V. Bezlyak, A. Sagkriotis, 2019, Vision.

The economic and humanistic burden of patients in receipt of current available therapies for nAMD.

D. Jaffe, V. Bezlyak, W. Chan, 2018, Journal of comparative effectiveness research.

Dispensing Patterns of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration: A Retrospective Cohort Study in Australia

F. Chen, V. Bezlyak, H. Carius, 2017, Advances in Therapy.

The economic and humanistic burden of patients in receipt of current available therapies for neovascular age-related macular degeneration

D. Jaffe, V. Bezlyak, W. Chan, 2018 .

Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers

M. Trojano, S. Vukusic, H. Butzkueven, 2023, Multiple sclerosis journal - experimental, translational and clinical.

Assessment of Clinical Meaningfulness of Endpoints in the Generation Program by the Insights to Model Alzheimer’s Progression in Real Life (iMAP) Study

P. Tariot, J. Langbaum, A. Gustavsson, 2018, The Journal of Prevention of Alzheimer's Disease.

Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence.

U. Chakravarthy, D. Boyer, V. Bezlyak, 2019, Ophthalmology. Retina.

Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

F. Fajnkuchen, V. Bezlyak, C. Prünte, 2015, British Journal of Ophthalmology.

Treatment patterns for retinal diseases in patients newly-treated with anti-VEGF agents: A retrospective analysis of claims data from the Japan Medical Data Center database

R. Kawasaki, Y. Ogura, M. Bauer, 2021, Japanese Journal of Ophthalmology.

406 Famotidine for the Prevention of Peptic Ulcers in Users of Low-Dose Aspirin. Placebo-Controlled Prospective Trial [Famous Trial]

V. Bezlyak, C. McCloskey, A. Taha, 2009 .

The impact of healthcare systems on the clinical diagnosis and disease-modifying treatment usage in relapse-onset multiple sclerosis: a real-world perspective in five registries across Europe

A. van der Walt, Ryan Ramanujam, V. Bezlyak, 2023, Therapeutic Advances in Neurological Disorders.